DNA Biomedical Solutions Ltd.: Preparations for pre-IND (505(b) (2) submission and expected capital raising by Entera; BeamMed retains a similar sales rate with a growing presence in the US; Target price remains unchanged.

DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.